|
rs6511720
|
LDLR
Intron 1
|
Common regulatory variant in the LDL receptor gene affecting LDLR expression,...
|
Heart & Inflammation
|
|
Strong
|
|
rs16947
|
CYP2D6
*2
|
Common CYP2D6 variant defining the *2 allele; previously considered normal-fu...
|
Pharmacogenomics
|
|
Strong
|
|
rs25531
|
SLC6A4
A>G
|
Promoter SNP near 5-HTTLPR that modifies serotonin transporter expression and...
|
Brain & Mental Health
|
|
Moderate
|
|
rs5030655
|
CYP2D6
*6
|
Frameshift deletion causing no enzyme function, defining poor metabolizer sta...
|
Pharmacogenomics
|
|
Established
|
|
rs28371725
|
CYP2D6
*41
|
Intronic splice variant causing decreased CYP2D6 enzyme activity through aber...
|
Pharmacogenomics
|
|
Established
|
|
rs776746
|
CYP3A5
*3
|
Splice site variant creating a non-functional CYP3A5 enzyme, dramatically aff...
|
Pharmacogenomics
|
|
Established
|
|
rs3918290
|
DPYD
*2A
|
Most critical pharmacogenomic variant causing complete loss of DPD enzyme fun...
|
Pharmacogenomics
|
|
Established
|
|
rs1800975
|
XPA
A23G
|
5' UTR variant in the XPA DNA damage recognition gene that modulates nucleoti...
|
Cancer Risk
|
|
Strong
|
|
rs67376798
|
DPYD
D949V
|
Decreased-function variant reducing DPD enzyme activity ~30%, requiring 50% f...
|
Pharmacogenomics
|
|
Established
|
|
rs1142345
|
TPMT
*3C
|
No-function variant causing deficient thiopurine methylation; most common TPM...
|
Pharmacogenomics
|
|
Established
|
|
rs6166
|
FSHR
Asn680Ser (N680S)
|
Affects FSH receptor sensitivity, determining ovarian response to FSH stimula...
|
Hormones & Sleep
|
|
Strong
|
|
rs1799971
|
OPRM1
A118G
|
Mu-opioid receptor variant affecting opioid response, pain sensitivity, and p...
|
Pharmacogenomics
|
|
Moderate
|
|
rs1045642
|
ABCB1
C3435T
|
Synonymous variant in P-glycoprotein affecting drug efflux pump expression an...
|
Pharmacogenomics
|
|
Moderate
|
|
rs4148323
|
UGT1A1
*6 Gly71Arg
|
Phase II glucuronidation enzyme that metabolizes bilirubin and many drugs inc...
|
Pharmacogenomics
|
|
Established
|
|
rs2740574
|
CYP3A4
*1B -392A>G
|
Promoter variant affecting CYP3A4 expression, most common in African populations
|
Pharmacogenomics
|
|
Moderate
|
|
rs116855232
|
NUDT15
Arg139Cys
|
Nucleotide diphosphatase that inactivates toxic thiopurine metabolites; reduc...
|
Pharmacogenomics
|
|
Established
|
|
rs2293275
|
LHCGR
Asn312Ser (N312S)
|
Affects LH/hCG receptor sensitivity near a glycosylation site, influencing ov...
|
Fertility & Reproductive Health
|
|
Strong
|
|
rs396991
|
FCGR3A
V158F
|
Missense variant in Fc gamma receptor IIIa (CD16a) that determines NK cell Ig...
|
Immune & Gut
|
|
Strong
|
|
rs5219
|
KCNJ11
E23K
|
Controls the pancreatic beta-cell potassium channel that regulates insulin se...
|
Nutrition & Metabolism
|
|
Strong
|
|
rs6923761
|
GLP1R
Gly168Ser
|
GLP-1 receptor variant that alters response to GLP-1 agonist medications used...
|
Pharmacogenomics
|
|
Moderate
|
|
rs3765467
|
GLP1R
Arg131Gln
|
Missense variant in the GLP-1 receptor that alters drug response to GLP-1 ago...
|
Pharmacogenomics
|
|
Moderate
|
|
rs10305492
|
GLP1R
A316T
|
Rare protective missense variant in the GLP-1 receptor associated with lower ...
|
Pharmacogenomics
|
|
Strong
|
|
rs1042044
|
GLP1R
Leu260Phe
|
GLP-1 receptor variant in intracellular loop 2 that alters receptor surface e...
|
Pharmacogenomics
|
|
Moderate
|
|
rs35599367
|
CYP3A4
*22
|
Intronic splice variant causing ~50% reduced CYP3A4 mRNA expression, affectin...
|
Pharmacogenomics
|
|
Established
|
|
rs622342
|
SLC22A1
A>C
|
Intronic variant in the OCT1 organic cation transporter reducing hepatic metf...
|
Pharmacogenomics
|
|
Moderate
|
|
rs12188300
|
IL12B
|
Near-gene variant at the IL12B locus associated with psoriasis risk through a...
|
Immune & Gut
|
|
Moderate
|
|
rs368234815
|
IFNL4
ss469415590 (TT/ΔG)
|
Causal frameshift polymorphism controlling IFNL4 protein production; the ΔG a...
|
Immune & Gut
|
|
Established
|